Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.34 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | MAP3K8 | P41279 | 1/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13826201 | 0.92 | CYP3A4 (0.46) | CYP3A4SLC22A12PSIP1MAP3K8 | |
| SCHEMBL15342231 | 0.84 | CYP3A4 (0.34) | CYP3A4PSIP1MEN1RAB9AKMT2A | |
| SCHEMBL15468858 | 0.84 | CYP3A4 (0.40) | CYP3A4SLC22A12PSIP1MEN1NPC1 | |
| SCHEMBL13733839 | 0.82 | CYP3A4 (0.32) | CYP3A4SLC22A12 | |
| SCHEMBL13733836 | 0.82 | CYP3A4 (0.32) | CYP3A4SLC22A12 | |
| SCHEMBL13733574 | 0.81 | NPC1 (0.38) | CYP3A4SLC22A12NPC1RAB9AKMT2A | |
| SCHEMBL13733571 | 0.81 | NPC1 (0.38) | CYP3A4SLC22A12NPC1RAB9AKMT2A | |
| SCHEMBL13733575 | 0.81 | NPC1 (0.38) | CYP3A4SLC22A12NPC1RAB9AKMT2A | |
| SCHEMBL15468970 | 0.81 | CYP3A4 (0.38) | CYP3A4PSIP1MEN1NPC1RAB9A | |
| SCHEMBL15468878 | 0.81 | CYP3A4 (0.38) | CYP3A4PSIP1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9879023-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170088554-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2017-03-30 | — | — | US | disclosed |
| US-9464096-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-20160024104-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-01-28 | — | — | US | disclosed |
| US-9006229-B2 | Benzothiazole compounds and their pharmaceutical use | GILEAD SCIENCES, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-20140045818-A1 | BENZOTHIAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. (US) | 2014-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170088554-A1 | THERAPEUTIC COMPOUNDS | FURIN, NFATC1, NPC1 | CYP3A4 3708/4885SLC22A12 600/4885PSIP1 2398/4885 |
| US-20140045818-A1 | BENZOTHIAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USE | FURIN, NFATC1, RUNX1 | CYP3A4 940/4885SLC22A12 842/4885PSIP1 1964/4885 |
| US-20160024104-A1 | THERAPEUTIC COMPOUNDS | NFATC1, FURIN, NPC1 | CYP3A4 3726/4885SLC22A12 615/4885PSIP1 2455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.